Lactobacillus delbrueckii subsp. bulgaricus LB340

Lactobacillus delbrueckii subsp. bulgaricus LB340 is a probiotic strain that produces lactic acid and exopolysaccharides, modulating gut barrier integrity and lipid metabolism through direct interaction with intestinal epithelial cells and systemic immune signaling. Its primary mechanism involves upregulating tight junction proteins such as ZO-1, occludin, and claudin-3 while influencing bile acid metabolism to alter circulating triglyceride levels.

Origin & History

Lactobacillus delbrueckii subsp. bulgaricus LB340 is a specific strain of lactic acid bacterium primarily originating from dairy fermentation processes, particularly yogurt production. It is sourced from milk fermentation cultures where it grows under controlled nutritional conditions, and derivatives like proteins and exopolysaccharides can be isolated from related strains via standard microbial extraction methods.

Historical & Cultural Context

No traditional medicine system or historical uses are documented for LB340 or L. delbrueckii subsp. bulgaricus in available sources. It is primarily recognized as a modern dairy fermentation starter for yogurt production, with functional probiotic roles identified only in recent research rather than ancient practices.

Health Benefits

• May reduce blood triglyceride levels and modulate lipid fractions in overweight adults (moderate evidence from one RCT, n=36)
• Protects against intestinal permeability by enhancing tight junction proteins like ZO-1, occludin, and claudin-3 (preliminary evidence from animal studies)
• Reduces inflammation and tissue edema in hypoxia conditions (preliminary evidence from mouse models, n=5-6 per group)
• Promotes wound healing through fibroblast proliferation and collagen production (preliminary evidence from in vitro studies showing 10-20% improvement)
• Helps rebalance intestinal microbiota composition (preliminary evidence from animal studies)

How It Works

LB340 produces lactic acid and bioactive exopolysaccharides that interact with Toll-like receptor 2 (TLR-2) on intestinal epithelial cells, triggering downstream NF-κB modulation and reducing pro-inflammatory cytokine release including IL-6 and TNF-α. The strain upregulates tight junction proteins ZO-1, occludin, and claudin-3 by activating the PI3K/Akt signaling pathway, reinforcing the intestinal epithelial barrier and reducing paracellular permeability. Additionally, LB340 influences bile salt hydrolase (BSH) activity, deconjugating bile acids in the gut lumen, which reduces bile acid reabsorption and redirects hepatic cholesterol toward bile acid synthesis, contributing to observed reductions in serum triglycerides and modulation of lipid fractions.

Scientific Research

Limited clinical evidence exists specifically for LB340 strain. One RCT (PMID: 38393021) tested an unnamed L. delbrueckii ssp. bulgaricus strain in 36 overweight adults at 1×10^8 CFU/day for 12 weeks, showing triglyceride reduction but no weight loss effects. Animal studies (PMID: 38794703, PMC11124140) demonstrated protective effects on intestinal barrier function and inflammation using related strains.

Clinical Summary

The primary human evidence for LB340 comes from a single randomized controlled trial (RCT) enrolling 36 overweight adults, which reported statistically significant reductions in blood triglyceride levels and favorable modulation of lipid fractions following supplementation. While these findings are promising, the small sample size and single-study basis limit the strength of conclusions, placing this evidence at a moderate level pending replication in larger cohorts. Animal model studies have provided preliminary mechanistic support for gut barrier protection, demonstrating increased expression of ZO-1, occludin, and claudin-3 in intestinal tissue, though these findings have not yet been confirmed in human trials. Anti-inflammatory effects attributed to LB340 are similarly supported by preclinical data, and well-powered human RCTs are needed before definitive clinical recommendations can be made.

Nutritional Profile

Lactobacillus delbrueckii subsp. bulgaricus LB340 is a probiotic bacterial strain with negligible direct macronutrient contribution at typical supplemental doses (approximately 1–10 billion CFU). Its bioactive value lies in its metabolic byproducts: produces L(+)-lactic acid (primary fermentation output, contributing to gut acidification), exopolysaccharides (EPS) with immunomodulatory properties, and bacteriocins with antimicrobial activity. During fermentation, this strain generates B-vitamins including folate (B9, estimated 0.1–0.5 µg/g in fermented substrates) and riboflavin (B2, ~0.2–0.8 µg/g), though concentrations vary by growth medium. It produces cell wall-associated peptidoglycans and lipoteichoic acids that directly interact with host Toll-like receptors (TLR-2). The strain generates short-chain peptides via proteolytic activity on casein, including bioactive tripeptides (IPP, VPP) when grown in dairy substrates. Bioavailability of its metabolites is high given their small molecular weight, though live cell survival through gastric transit is moderate (~10–40% viability at gastric pH 2.0) without encapsulation. Its lipid-modulating effects are attributed in part to bile salt hydrolase (BSH) activity, which deconjugates bile acids and reduces cholesterol reabsorption.

Preparation & Dosage

The clinically studied dosage for L. delbrueckii ssp. bulgaricus (unnamed strain, not LB340-specific) is 1×10^8 CFU/day as powder for 12 weeks, based on one trial in overweight adults. No specific dosage data exists for LB340 strain in human trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

LB340 pairs strongly with Streptococcus thermophilus, its classical yogurt co-culture partner, which produces formate and CO2 that stimulate LB340 growth while LB340's proteolytic activity supplies S. thermophilus with free amino acids — together, this protocooperation amplifies EPS production and lactic acid output by 30–50% compared to monocultures. Prebiotic inulin or fructooligosaccharides (FOS, 3–5g dose) selectively feed Lactobacillus strains in the colon, increasing LB340 metabolite production including lactic acid and EPS while simultaneously enhancing tight junction protein expression synergistically with LB340's own ZO-1/occludin upregulation pathway. Omega-3 fatty acids (EPA/DHA, 1–2g/day) complement LB340's anti-inflammatory and triglyceride-lowering mechanisms through independent but additive pathways — LB340 acts via BSH-mediated bile acid deconjugation and lipid metabolism modulation, while EPA/DHA directly suppress hepatic VLDL synthesis and activate PPARα, potentially producing greater combined triglyceride reduction than either intervention alone.

Safety & Interactions

Lactobacillus delbrueckii subsp. bulgaricus LB340 is generally considered safe for healthy adults, consistent with the broad GRAS (Generally Recognized as Safe) status granted to most Lactobacillus species by regulatory authorities. Mild gastrointestinal side effects such as bloating, gas, or loose stools may occur during the initial days of supplementation as the gut microbiome adjusts. Immunocompromised individuals, those with short bowel syndrome, or patients with central venous catheters should consult a physician before use, as rare cases of Lactobacillus bacteremia have been documented in vulnerable populations with other probiotic strains. No specific drug interactions for LB340 have been established, though concurrent use of broad-spectrum antibiotics will reduce its viability, and caution is advised in individuals taking immunosuppressant medications; safety during pregnancy and lactation has not been specifically studied for this strain.